Project Grant HT94252310714
Award Date
7/1/23
Completion Date
6/30/26
Dollars Obligated
$438K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
The U.S. Department of Defense's Defense Health Agency has awarded a $466,234 Project Grant to the University of Queensland in Australia to conduct "PROOF-OF-CONCEPT STUDIES FOR A NOVEL IMMUNOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER AND COMPANION DIAGNOSTIC." This research grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments and diagnostic tools to improve care for military service members, veterans, and their...
The University of New South Wales (UNSW) was awarded a $2,059,003.85 Project Grant from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public. Specifically, the funding will enable UNSW to conduct research aimed at understanding and overcoming resistance to new and emerging therapies in...
This $125,050 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research by the University of New South Wales (UNSW) to investigate the use of UDP-glucose in inducing ovarian cancer cell death and promoting antitumor immunity. The research aims to advance the understanding of therapeutic approaches for ovarian cancer, with the ultimate completion date of June 30, 2026. As a leading Australian research...
The U.S. Defense Health Agency has awarded a $367,622 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to St. Vincent's Institute of Medical Research, a foreign-owned non-profit organization based in Australia. The grant supports a 2-year research project focused on studying the reprogramming of mRNA translation as a driver of drug resistance in ovarian cancer. The research aims to transform healthcare for military service members and the broader public...
The U.S. Department of the Army Medical Command awarded a $5,835,803 Project Grant to the University of New South Wales (UNSW) on March 1, 2025 under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant will fund the development of a Breast Cancer Cellular Atlas, an advanced biomedical research initiative focused on transforming healthcare for military service members and the broader public. This 4-year research project will explore innovative approaches...
The University of New South Wales received a $555,506.43 three-year Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund a study titled "DUAL EPITHELIAL AND STROMAL TARGETING IN BREAST CANCER USING THE PHASE II ROCK2 INHIBITOR KD025 GUIDED BY INTRAVITAL IMAGING TECHNOLOGY" from March 1, 2022 to February 28, 2025. Through this award, the University will conduct research into investigating...
The Department of Defense's Defense Health Agency awarded a $1,205,784 Project Grant to Queensland University of Technology (QUT) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "ACCELERATING TRANSLATION OF A NOVEL METAP2 INHIBITOR IN TREATMENT-RESISTANT AND AGGRESSIVE-VARIANT PROSTATE CANCER," runs from July 1, 2024 to June 30, 2027. The project aims to accelerate the translation of a novel MetAP2 inhibitor therapy for treating...
The Defense Health Agency awarded a $744,997 Project Grant to the University of Queensland in Australia under the Military Medical Research and Development program (CFDA 12.420). This grant, titled "DISCOVERING THERAPEUTIC VULNERABILITIES OF CIRCULATING MELANOMA CLUSTERS," provides funding for the university to conduct cutting-edge biomedical research on melanoma from June 1, 2024 through May 31, 2027. The University of Queensland, a leading research institution in Australia, has an...
This $565,606 Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) is supporting research at Duke University to investigate the role of the macro lncRNA KCNQ1OT1 in rhabdomyosarcoma tumorigenesis. The university is collaborating with researchers at the University of North Carolina Chapel Hill and St. Jude Children's Research Hospital on this effort. Key goals include determining the phenotypic and genotypic effects of KCNQ1OT1...
The Defense Health Agency awarded a $4,319,388 Project Grant to the University of Melbourne to fund research aimed at "TARGETING SENESCENT CELLS TO IMPROVE OUTCOMES FOR BREAST CANCER PATIENTS" over the period from September 1, 2024 to August 31, 2028. This grant is provided under the Military Medical Research and Development Program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...